Bromodomain inhibition overcomes treatment resistance in distinct molecular subtypes of melanoma

Therapy of BRAF-mutant melanoma with selective inhibitors of BRAF (BRAFi) and MEK (MEKi) represents a major clinical advance but acquired resistance to therapy has emerged as a key obstacle. To date, no clinical approaches successfully resensitize to BRAF/MEK inhibition. Here, we develop a therapeut...

Descripción completa

Detalles Bibliográficos
Autores principales: Dar, Altaf A., Bezrookove, Vladimir, Nosrati, Mehdi, Ice, Ryan, Patino, John M., Vaquero, Edith M., Parrett, Brian, Leong, Stanley P., Kim, Kevin B., Debs, Robert J., Soroceanu, Liliana, Miller, James R., Desprez, Pierre-Yves, Cleaver, James E., Salomonis, Nathan, McAllister, Sean, Kashani-Sabet, Mohammed
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2022
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407673/
https://www.ncbi.nlm.nih.gov/pubmed/35969744
http://dx.doi.org/10.1073/pnas.2206824119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9407673/
https://www.ncbi.nlm.nih.gov/pubmed/35969744
http://dx.doi.org/10.1073/pnas.2206824119

Ejemplares similares